Evaluating mismatch repair deficiency in colorectal cancer biopsy specimens
-
Published:2023-06-07
Issue:2
Volume:160
Page:113-125
-
ISSN:0948-6143
-
Container-title:Histochemistry and Cell Biology
-
language:en
-
Short-container-title:Histochem Cell Biol
Author:
Grillo F.ORCID, Paudice M.ORCID, Gambella A.ORCID, Bozzano S., Sciallero S., Puccini A.ORCID, Lastraioli S., Dono M.ORCID, Parente P.ORCID, Vanoli A., Angerilli V., Fassan M., Mastracci L.ORCID
Abstract
AbstractMismatch repair (MMR) testing on all new cases of colorectal cancer (CRC) has customarily been preferably performed on surgical specimens, as more tissue is available; however, new clinical trials for the use of immune checkpoint inhibitors in the neoadjuvant setting require MMR testing on biopsy samples. This study aims at identifying advantages, disadvantages and any potential pitfalls in MMR evaluation on biopsy tissue and how to cope with them. The study is prospective-retrospective, recruiting 141 biopsies (86 proficient (p)MMR and 55 deficient (d)MMR) and 97 paired surgical specimens (48 pMMR; 49 dMMR). In biopsy specimens, a high number of indeterminate stains was observed, in particular for MLH1 (31 cases, 56.4%). The main reasons were a punctate nuclear expression of MLH1, relatively weak MLH1 nuclear expression compared to internal controls, or both (making MLH1 loss difficult to interpret), which was solved by reducing primary incubation times for MLH1. A mean of ≥ 5 biopsies had adequate immunostains, compared to ≤ 3 biopsies in inadequate cases. Conversely, surgical specimens rarely suffered from indeterminate reactions, while weaker staining intensity (p < 0.007) for MLH1 and PMS2 and increased patchiness grade (p < 0.0001) were seen. Central artefacts were almost exclusive to surgical specimens. MMR status classification was possible in 92/97 matched biopsy/resection specimen cases, and all of these were concordant (47 pMMR and 45 dMMR). Evaluation of MMR status on CRC biopsy samples is feasible, if pitfalls in interpretation are known, making laboratory-specific appropriate staining protocols fundamental for high-quality diagnoses.
Funder
Università degli Studi di Genova
Publisher
Springer Science and Business Media LLC
Subject
Cell Biology,Medical Laboratory Technology,Molecular Biology,Histology
Reference46 articles.
1. Adar T, Rodgers LH, Shannon KM, Yoshida M, Ma T, Mattia A, Lauwers GY, Iafrate AJ, Chung DC (2017) A tailored approach to BRAF and MLH1 methylation testing in a universal screening program for Lynch syndrome. Mod Pathol 30:440–447. https://doi.org/10.1038/modpathol.2016.211 2. Bartley AN, Mills AM, Konnick E, Overman M, Ventura CB, Souter L, Colasacco C, Stadler ZK, Kerr S, Howitt BE, Hampel H, Adams SF, Johnson W, Magi-Galluzzi C, Sepulveda AR, Broaddus RR (2022) Mismatch repair and microsatellite instability testing for immune checkpoint inhibitor therapy: guideline from the College of American Pathologists in collaboration with the Association for Molecular Pathology and Fight Colorectal Cancer. Arch Pathol Lab Med 146:1194–1210. https://doi.org/10.5858/arpa.2021-0632-CP 3. Bragoni A, Gambella A, Pigozzi S, Grigolini M, Fiocca R, Mastracci L, Grillo F (2017) Quality control in diagnostic immunohistochemistry: integrated on-slide positive controls. Histochem Cell Biol 148:569–573. https://doi.org/10.1007/s00418-017-1596-y 4. Cercek A, Lumish M, Sinopoli J, Weiss J, Shia J, Lamendola-Essel M, El Dika IH, Segal N, Shcherba M, Sugarman R, Stadler Z, Yaeger R, Smith JJ, Rousseau B, Argiles G, Patel M, Desai A, Saltz LB, Widmar M, Iyer K, Zhang J, Gianino N, Crane C, Romesser PB, Pappou EP, Paty P, Garcia-Aguilar J, Gonen M, Gollub M, Weiser MR, Schalper KA, Diaz LA Jr (2022) PD-1 blockade in mismatch repair deficient, locally advanced rectal cancer. N Engl J Med 386:2363–2376. https://doi.org/10.1056/NEJMoa2201445 5. Chalabi M, Verschoor YL, van den Berg J, Sikorska K, Beets G, Lent AV, Grootscholten MC, Aalbers A, Buller N, Marsman H, Hendriks E, Burger PWA, Aukema T, Oosterling S, Beets-Tan R, Schumacher TN, van Leerdam M, Voest EE, Haanen JBAG (2022) Neoadjuvant immune checkpoint inhibition in locally advanced MMR-deficient colon cancer: the NICHE-2 study. Ann Oncol. https://doi.org/10.1016/annonc/annonc1089
Cited by
7 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
|
|